VetCell Bioscience Ltd now MedCell Bioscience Ltd

1
VetCell Bioscience Ltd(now MedCell Bioscience
Ltd)

• David Mountford
• Chief Operating Officer

2
MedCell BioScience

• Revenue generating stem cell company
• IP and know-how in a revolutionary stem cell
  treatment for tendon ligament injuries where
  there is a major unmet need .
• Commercialised in the veterinary market.
• Now poised to exploit the human healthcare field.
• Seeking funds to translate the technology for the
  human market and exploit the veterinary market.

3
A BioEntrepreneurial Company?

• Innovation
• Entrepreneurship
• Strong management
• Plans for expansion
• Potential value

4
Innovation

• Autologous stem cell implantation providing the
  potential to regenerate functional tendon or
  ligament tissue
• Innovative combination of expanded cells,
  autologous scaffold, and growth factor rich
  carrier combined with a clinically
  straightforward application
• Developed at
• Institute of Orthopaedics Musculoskeletal
  Science (UCL)
• Royal Veterinary College

5
Need

• Tendon ligament injuries repair with scar
  tissue
• Scar limits efficiency and increases incidence of
  re-injury
• Goals
• Therapy which regenerates tendon/ligament tissue
• Therapy which is clinically applicable /
  affordable

6
(No Transcript)
7
Clinical Outcome Measures
Return to Racing
No Re-injury
8
Achievements

• Technology developed to a commercial offering
• Regulatory compliance secured
• Wholly owned patent family
• Revenue generating with expanding portfolio
• Established internationally
• Commercially active in 19 countries
• 7 labs worldwide
• Winner UKTI Outstanding Achievement in Export
  2007
• Over 500 performance horses treated

9
Territories
Laboratories
Opinion Leaders
10
Strategic Alliances
Vet Biotechnology
11
(No Transcript)
12
Entrepreneurship

• Achievements
• Unconventional approach - animal health market
  first
• Named patient
• Life and death unmet need
• Creative deals
• Investment to date of only 850k
• Blood sweat and tears

13
Market Opportunity in Man

• Achilles tendinopathy affects 7-18 club runners
• 1 in 10,000 people suffer an ankle inversion
  sprain each day.
• 30-50 of all US sports injuries are tendon
  overuse injuries.
• Tendon problems account for almost 30 of all
  running injuries and 40 of all tennis injuries.
• Rotator cuff injury (RCI)
• c2.4m new RCIs p.a.
• Potential market (RCIs alone) 4.8bn
• Incidence of tendon overuse injuries increases
  with age

14
The Next 3 Years

• Exploratory and confirmatory clinical studies in
  man
• Achilles tendinopathy
• RCI
• Patellar tendonitis
• Named patient service
• Growth of human commercial programme via
  out-licensing, trade sale, or IPO funded business
  expansion
• Development of further therapeutic applications
• International expansion of veterinary business
  and portfolio

15
Key People

• Chair Dr David Glover MA (Cantab) MB BChir
  MRCP FFPM
• Former Medical Director at CAT with outstanding
  industry credentials
• CEO Greg McGarrell CVT Dip.M MBA
• CEO with proven experience in industry start-ups
• COO David Mountford MA (Cantab) VetMB MRCVS
• Global operational and management experience in
  animal health industry
• CFO Jon Dooley MA (Cantab) FCA
• Experienced in acquisitions, disposals, and
  leading flotation/NASDAQ processes.
• CSO Prof. Roger Smith MA (Cantab) VetMB PhD DEO
  DipECVS MRCVS
• World renowned expert in tendon and ligament
  disease.

16
Building the team

• Chief Medical Officer
• Commercial Director
• Product Development Manager
• Sales team (animal health)
• General Manager (VetCell Bioscience Inc.)

17
Financial Projections

• On the basis of the predicted revenues and costs
  the Company aims to
• move into sustainable profit by 2011
• generate a 16M pre-tax profit in 2013.
• Ongoing success with treatments and follow on
  products should enable growth and profitability
  to continue to rise.

18
A BioEntrepreneurial Company

• Innovation
• Entrepreneurship
• Strong management
• Plans for expansion
• Potential value

19
MedCell Bioscience Ltd(formerly VetCell
Bioscience Ltd)